To evaluate demographic and clinical predictors of early renal function decline following nephrectomy in patients with renal cell carcinoma (RCC) or upper tract urothelial carcinoma (UTUC), emphasizing the importance of identifying these predictors for improved patient outcomes.
Key Findings:
41.8% of patients experienced rapid eGFR decline, indicating a significant risk in this population.
Significant predictors of rapid decline included diabetes (OR 1.56) and postoperative AKI (OR 1.85), highlighting the need for targeted interventions.
Risk stratification showed a stepwise increase in rapid decline incidence based on the presence of diabetes and AKI, suggesting a need for tailored monitoring strategies.
Interpretation:
Diabetes and postoperative AKI are critical independent predictors of early renal function decline after nephrectomy, underscoring the necessity for targeted postoperative monitoring and intervention to improve patient outcomes.
Limitations:
The study is retrospective, which may introduce biases in data collection and analysis.
Findings may not be generalizable to populations outside of the study cohort, limiting broader applicability.
Conclusion:
Identifying patients at high risk for renal function decline post-nephrectomy can improve postoperative care and outcomes.
REGENXBIO reports phase III AAV data in Duchenne; plus: adenoviral immunotherapy, preconditioning-free CAR-T, in vivo immune programming, and DNA-guided CRISPR
